Bavarian Nordic stock zooms ~62% on smallpox vaccine Imvanex deal in Europe to fight monkeypox
blackdovfx/iStock via Getty Images
- Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) said it secured a contract with an undisclosed European country to supply its Imvanex smallpox vaccine in response to new cases of monkeypox in May.
- The Denmark-based company's stock rose ~62% to $30.48 on May 19 in US trading. Meanwhile, the shares closed +29.46% to DKK183 May 19 on the Copenhagen Stock Exchange where it trades under the ticker BAVA.
- While the first European case was confirmed on May 7, more than 20 cases have been confirmed in England, Portugal and Spain, said the company in a May 19 press release.
- Bavarian said its smallpox vaccine is approved in the U.S. as Jynneos and in Canada as Imvamune. In both countries the approval extends to cover the monkeypox indication.
- The company added that Imvanex is approved in Europe for smallpox but has previously been provided for off-label use in response to monkeypox cases.
- The order has no impact on Bavarian's guidance for 2022, said the company.